Cocrystal Pharma (COCP) Research & Development (2010 - 2026)

Cocrystal Pharma (COCP) has 16 years of Research & Development data on file, last reported at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 0.81% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $5.1 million (down 53.72% YoY), and the FY2025 full-year result was $5.1 million, down 59.68% from the prior year.
• Research & Development eased to $1.4 million in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $4.3 million in Q2 2024 to a low of $954000.0 in Q3 2025.
• A 5-year average of $2.7 million and a median of $2.9 million in 2022 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 83.94% in 2022 and plunged 73.96% in 2025, its largest moves.
• Tracing COCP's Research & Development over 5 years: stood at $3.3 million in 2022, then grew by 29.81% to $4.3 million in 2023, then sank by 52.26% to $2.0 million in 2024, then decreased by 20.52% to $1.6 million in 2025, then slipped by 15.32% to $1.4 million in 2026.
• Business Quant data shows COCP's Research & Development at $1.4 million in Q1 2026, $1.6 million in Q4 2025, and $954000.0 in Q3 2025.